Kwality Pharmaceuticals Ltd. (KPL) Share Price Trades Within 2% of 52-Week High
- August 11, 2026
- Posted by: Harsh Piplani
- Category: News
Kwality Pharmaceuticals Ltd. Share Price is Rs 3,117, with the stock trading within 2% of its 52-week high. The company’s market capitalisation stands at Rs 2,707.2 crore.
Kwality Pharmaceuticals Ltd. Share Price is at Rs 3,117, and the stock is trading within 2% of its 52-week high, placing the counter on the radar of investors tracking momentum, valuation and sector positioning. With a market capitalisation of Rs 2,707.2 crore, the company sits in the mid-sized range within the listed pharmaceuticals and drugs space, which makes its price position notable in a broader healthcare screen.
The verified Univest screener data confirms the proximity event at an LTP of Rs 3,117 on 11 August 2026 at 12:30:46 PM IST. That matters because stocks trading close to one-year highs often attract additional attention from market participants looking at strength, rerating potential and relative sector performance. In this case, the supplied data confirms the price event but does not establish a company-specific catalyst.
Beyond the headline price move, the available numbers provide a useful framework for analysis. Kwality Pharmaceuticals Ltd. Share Price is being discussed not only because of its position near a yearly high, but also because the company combines a P/E of 40.09, P/B of 9.77, ROE of 28.21 and ROCE of 26.35 with a market value that is above most companies in its same-industry benchmark set tracked by Univest.
Kwality Pharmaceuticals Ltd. Share Price Today: Within 2% of 52-Week High
| Metric | Value |
|---|---|
| LTP at 2% Qualification | Rs 3,117 |
| Market Capitalisation | Rs 2,707.2 crore |
| 52-Week High Position | Trading within 2% of its 52-week high |
Kwality Pharmaceuticals Ltd. (KPL) traded at Rs 3,117. Reported volume was 41,690.
Kwality Pharmaceuticals Ltd. Share Price Today stands at Rs 3,117 based on the event-time LTP captured by the Univest screener. The stock has been identified as trading within 2% of its 52-week high, which means it is close to its one-year peak without implying that it has touched or crossed that reference level. For active market watchers, that kind of setup often matters because proximity to a yearly high can draw fresh scanning activity from traders, investors and sector analysts.
The available price dataset for this event is intentionally narrow and confirms the most important fact: Kwality Pharmaceuticals Ltd. Share Price is near the upper end of its 12-month trading range. That, by itself, is relevant because stocks near annual highs are often assessed for durability of momentum, relative valuation and whether financial quality supports the attention they are receiving.
At Rs 3,117, the company’s market capitalisation of Rs 2,707.2 crore gives this move additional context. It is not a very small micro-cap name where sharp price moves can be ignored as illiquid noise; it is a company with meaningful listed scale in the Pharmaceuticals & Drugs industry. For readers following Kwality Pharmaceuticals Ltd. Stock News, the present setup suggests the market is paying attention to a stock that is already priced at a premium to several industry medians, while still delivering strong return ratios. That naturally shifts the discussion from pure price action to whether the fundamentals justify continued interest.
Kwality Pharmaceuticals Ltd. (KPL) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 2,707.2 crore |
| P/E Ratio | 40.09x |
| P/B Ratio | 9.77x |
| ROE | 28.21% |
| ROCE | 26.35% |
| EPS | Rs 78.1 |
| Book Value Per Share | Rs 318.8 |
| Dividend Yield | 0% |
Kwality Pharmaceuticals Ltd. was valued at a P/E ratio of 40.09x, a P/B ratio of 9.77x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of 28.21% and ROCE of 26.35%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Per-share and shareholder-return metrics included EPS of Rs 78.1, book value per share of Rs 318.8, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 40.09x |
| Benchmark Median P/E | 18.46x |
| Benchmark Average P/E | 52.67x |
| Benchmark P/E Range | 0x to 3,396.3x |
| Company P/B Ratio | 9.77x |
| Benchmark Median P/B | 1.78x |
| Company ROE | 28.21% |
| Benchmark Median ROE | 10.21% |
| Company ROCE | 26.35% |
| Benchmark Median ROCE | 12.96% |
| Company Market Capitalisation | Rs 2,707.2 crore |
| Benchmark Median Market Cap | Rs 146.63 crore |
Kwality Pharmaceuticals Ltd. (KPL) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Kwality Pharmaceuticals Ltd. (KPL) has a P/E ratio of 40.09x, which is above the benchmark median of 18.46x, a difference of +117.17%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Kwality Pharmaceuticals Ltd. (KPL) has a ROE of 28.21%, which is above the benchmark median of 10.21%, a difference of +176.3%. Kwality Pharmaceuticals Ltd. (KPL) has a ROCE of 26.35%, which is above the benchmark median of 12.96%, a difference of +103.32%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Beta Drugs Ltd. | BETA | 2,631.45 | 66.92 | 10.59 | 18.65 | 22.17 |
| Sai Parenteral's Ltd. | SAIPARENT | 2,513.58 | 181.97 | 3.36 | 13.9 | 12.97 |
| NGL Fine-Chem Ltd. | NGLFINE | 2,118.6 | 44.48 | 6.5 | 27.9 | 33.91 |
| Venus Remedies Ltd. | VENUSREM-BE | 2,068.61 | 17.49 | 2.96 | 9.85 | 7.89 |
| Hester Biosciences Ltd. | HESTERBIO | 2,057.85 | 15.63 | 4.68 | 16.17 | 14.12 |
Kwality Pharmaceuticals Ltd. (KPL) has a P/E ratio of 40.09x compared with the displayed peer median of 44.48x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 28.21% compares with a peer median of 16.17% across the companies shown in the table. ROCE stood at 26.35% versus the displayed peer median of 14.12%, providing a capital-efficiency comparison. Kwality Pharmaceuticals Ltd. (KPL) has a market capitalisation of Rs 2,707.2 crore. Among the 5 peers shown, 0 have a larger market capitalisation.
Why Investors Are Watching Kwality Pharmaceuticals Ltd.
- Kwality Pharmaceuticals Ltd. Share Price is at Rs 3,117 and the stock is trading within 2% of its 52-week high.
- The company’s market capitalisation is Rs 2,707.2 crore, making it a meaningful listed player in Pharmaceuticals & Drugs.
- Valuation is elevated versus industry medians, with P/E at 40.09 and P/B at 9.77.
- Profitability is strong, with ROE of 28.21 and ROCE of 26.35, both above same-industry medians and averages.
- EPS of Rs 78.1 and book value of Rs 318.8 add operating and balance-sheet context to the current pricing.
- Peer comparisons show the stock sits in a premium zone, but not without support from stronger return ratios than several peers.
About Kwality Pharmaceuticals Ltd.
Kwality Pharmaceuticals Ltd. is classified in the Healthcare sector and the Pharmaceuticals & Drugs industry. Based on the supplied dataset, the company is being analysed in the context of listed pharmaceutical peers and same-industry valuation and profitability benchmarks rather than through a broad diversified-business lens.
That matters because investors generally assess pharmaceutical companies through a mix of earnings valuation, return on equity, return on capital employed and relative market size within the industry. In the case of Kwality Pharmaceuticals Ltd., the market capitalisation of Rs 2,707.2 crore places it among the larger companies in the relevant same-industry benchmark used here. Its position near a 52-week high therefore attracts attention not only as a price event, but also as a sector-specific signal within a competitive healthcare listing universe.
For readers following Kwality Pharmaceuticals Ltd. Share Price and Kwality Pharmaceuticals Ltd. Stock News, the company’s market position in this article is defined by its place inside the pharmaceuticals peer group, where it combines above-median scale with above-median profitability and premium valuation ratios.
Track Kwality Pharmaceuticals Ltd. Share Price on Univest
Use Kwality Pharmaceuticals Ltd. (KPL) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Investors tracking Kwality Pharmaceuticals Ltd. Share Price can use Univest to monitor live price movement, 52-week levels, valuation ratios, profitability indicators, sector comparisons and peer snapshots in one place. For a stock that is currently trading within 2% of its 52-week high, that consolidated view is useful because it helps separate headline price attention from underlying financial context.
Univest also allows users to follow how Kwality Pharmaceuticals Ltd. Share Price Today compares with sector medians, peer multiples and return ratios over time. That makes the platform relevant not only for daily stock-market monitoring, but also for structured stock analysis built around fundamentals, peer positioning and broader healthcare sector benchmarks.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is Kwality Pharmaceuticals Ltd. Share Price today?
Ans. Kwality Pharmaceuticals Ltd. Share Price today is Rs 3,117 based on the event-time LTP captured on 11 August 2026 at 12:30:46 PM IST. The same verified screener reading also identified the stock as trading within 2% of its 52-week high.
Why is Kwality Pharmaceuticals Ltd. Share Price in focus?
Ans. Kwality Pharmaceuticals Ltd. Share Price is in focus because the stock is trading within 2% of its 52-week high. The company also has a market capitalisation of Rs 2,707.2 crore and strong profitability metrics, including ROE of 28.21 and ROCE.
Is Kwality Pharmaceuticals Ltd. near its 52-week high?
Ans. Yes, the Univest screener identified Kwality Pharmaceuticals Ltd. Share Price as trading within 2% of its 52-week high. The event was qualified at an LTP of Rs 3,117, which places the stock close to its one-year peak range.
What are the key valuation ratios for Kwality Pharmaceuticals Ltd.?
Ans. Kwality Pharmaceuticals Ltd. currently trades at a P/E ratio of 40.09 and a P/B ratio of 9.77. These multiples are above the same-industry medians, indicating the market is valuing the business at a premium to many listed peers.
How profitable is Kwality Pharmaceuticals Ltd. based on supplied data?
Ans. The supplied figures show ROE of 28.21 and ROCE of 26.35 for Kwality Pharmaceuticals Ltd. Both are above the same-industry median levels of 10.21 and 12.96 respectively, pointing to stronger profitability than the benchmark centre.
What do EPS, book value and dividend yield show for Kwality Pharmaceuticals Ltd.?
Ans. Kwality Pharmaceuticals Ltd. reports EPS of Rs 78.1, book value per share of Rs 318.8 and dividend yield of 0. This indicates the current dataset highlights earnings and balance-sheet value rather than a dividend-based return profile.
How does Kwality Pharmaceuticals Ltd. compare with its industry benchmark?
Ans. In a same-industry benchmark of 136 companies, Kwality Pharmaceuticals Ltd. has a P/E of 40.09 versus a median of 18.46, while ROE of 28.21 and ROCE of 26.35 are above benchmark medians of 10.21 and 12.96.
How does Kwality Pharmaceuticals Ltd. compare with peers like Beta Drugs and NGL Fine-Chem?
Ans. Kwality Pharmaceuticals Ltd. has a lower P/E than Beta Drugs and Sai Parenteral's, while its ROE is slightly above NGL Fine-Chem. Its ROCE trails NGL Fine-Chem, but the company’s market capitalisation of Rs 2,707.2 crore is higher than all five.
